Program
GKL-006
A development code. Also written as “GKL-006 Injection” and “GKL-006 injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Pancreatic Neoplasms, led by Beijing Gene Key Life Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Gene Key Life Technology | 43 open or running | phase 2since Sep 29, 2025 | Sep 29, 2025 | Mar 31, 2027phase 2 · NCT07777211 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT07209813 · 48 planned · China
- Jun 12, 2026Phase 1 study in Carcinoma, HepatocellularNCT07713290 · 6 enrolled · China
- Aug 17, 2026Phase 2 study in Advanced Pancreatic CancerNCT07777211 · 52 planned · China
- Sep 22, 2026Phase 1 study in Carcinoma, HepatocellularNCT07845266 · 13 enrolled · China
Ahead
- Nov 12, 2026Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07713290
- Mar 31, 2027Primary completion: phase 2 study in Advanced Pancreatic CancerNCT07777211
- Sep 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07209813
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07845266Carcinoma, Hepatocellular · China | 1 | Completed | Apr 9, 2025 | 13 |
| NCT07777211Advanced Pancreatic Cancer · China | 2 | Recruiting | Mar 31, 2027 | 52 |
| NCT07713290Carcinoma, Hepatocellular · China | 1 | Active, not recruiting | Nov 12, 2026 | 6 |
| NCT07209813Carcinoma, Hepatocellular · China | 2 | Recruiting | Sep 30, 2027 | 48 |
How it is read
Names in the registry
- “GKL-006 Injection”, 3 entries
- “GKL-006 injection”, 1 entry
Codes read as this program: GKL006.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 3 studies
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.